Paul Kelly Marcom, MD

Related Content

Services

• Breast Cancer
• Hereditary Cancer

Department / Division:
Medicine / Medical Oncology

Address:
DUMC 3147
Durham, NC 27710

Appointment Telephone:
(919) 668-6688
Hereditary Cancer Clinic: (919) 684-3181

Office Telephone:
(919) 684-3877

Fax Telephone:
(919) 681-0874

• M.D., Baylor College of Medicine, Texas, 1989

• Medicine, Duke University Medical Center, North Carolina, 1989-1992
• Hematology and Oncology, Duke University Medical Center, North Carolina, 1992-1995

• Post-Doctoral Fellow, Duke University Medical Center, North Carolina, 1995-1997

Clinical Interests:
Breast cancer prevention and treatment, hereditary cancer syndromes, cell cycle control alterations in cancer

Research Interests:
Basic Science:  
-Germline and somatic genetic changes in cancer, particularly breast cancer.  Ongoing efforts with Dr. Joseph R. Nevins in Department of Genetics.

Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer

Dr. Marcom's research has focused on two main areas.  First, in the laboratory of Dr. Joseph Nevins in the Department of Genetics, he has been investigating alterations in cell cycle control in cancer. Primarily, these experiments have looked for primary alterations in the E2F family of genes, and their possible contribution to developing cancer. More recently, he has been involved with issues regarding genetic predisposition to developing cancer.

Investigations of cell cycle alterations have employed standard molecular biology techniques to analyze both cell lines and primary tumors for alterations in control of the retinoblastoma pathway, and consequent effects on E2F control.

Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments. In addition, he is developing a new high risk, familial cancer clinic. This clinic will see patients and families thought to be at high risk of developing malignancies, and will interface with the forming Cancer Genetics Network. Patients and families will be counseled about their cancer risk, and identified for studying issues related to cancer genetics: determining penetrance of identified gene mutations, determining factors modifying genetic risk, prevention studies, etc. Finally, he also plans to be involved in clinical evaluation of drugs inhibiting tumor angiogenesis.

Areas of developing expertise include cell cycle alterations in malignancy, breast cancer, and hereditary cancer genetics.

Breast cancer, cell cycle, genetics, familial cancer, prognostic factors, angiogenesis

Representative Publications:
Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 1;23(4):792-9. (2005) Abstract

Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, Liotcheva VB, Jones EL, Vujaskovic Z, Marks J, Dewhirst MW, West M, Nevins JR, Blackwell K. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):819-26. (2006) Abstract

Bean GR, Scott V, Yee L, Ratliff-Daniel B, Troch MM, Seo P, Bowie ML, Marcom PK, Slade J, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Baker JC Jr, Wilke LG, Seewaldt VL. Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):790-8. (2005) Abstract

Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005 Aug 10;23(23):5305-13. (2005) Abstract

Kirkland KB, Marcom PK, Sexton DJ, Dumler JS, Walker DH. Rocky Mountain spotted fever complicated by gangrene: report of six cases and review. Clin Infect Dis. 1993 May;16(5):629-34. (1993) Abstract

Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005 Apr 10;23(11):2502-12. (2005) Abstract

Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19;95(6):491-2. (2003) Abstract

Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC Jr, Troch MM, Paisie C, Wilke LG, Yee L, Marcom PK, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Scott V, Seewaldt VL. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):50-6. (2007) Abstract

(4) Miron AE, Schildkraut JM, Rimer BK, Winer EP, Skinner CS, Futreal PA, Culler D, Calingaert B, Clark S, Marcom PK, Iglehart JD. Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States. Annals of Surgery, 231 (5): 624-633, 2000. (2000)

Noebels JL, Marcom PK, Jalilian-Tehrani MH. Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion. Nature. 1991 Aug 1;352(6334):431-4. (1991) Abstract

Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep;10(9):1113-6. (1999) Abstract

Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K, Rimer BK. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001 May 1;19(9):2381-9. (2001) Abstract

Ortel TL, Charles LA, Keller FG, Marcom PK, Oldham HN Jr, Kane WH, Macik BG. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994 Feb;45(2):128-35. (1994) Abstract

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 1;21(15):2889-95. (2003) Abstract

Vujaskovic Z, Jones EL, Prosnitz LR, Marcom PK, Hardenbergh PH, Marks LB, Samulski TV, Brizel DM, Dewhirst MW. Concurrent chemotherapy, hyperthermia and radiotherapy improve reoxygenation in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2 Suppl):S357. (2003) Abstract

Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002 Summer;6(2):93-105. (2002) Abstract

Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK. Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II Study. J Clin Oncol. 2004 Jun 15;22(12):2321-7. (2004) Abstract

Jones EL, Prosnitz LR, Dewhirst MW, Marcom PK, Hardenbergh PH, Marks LB, Brizel DM, Vujaskovic Z. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res. 2004 Jul 1;10(13):4287-93. (2004) Abstract

Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2006 Aug 8. (2006) Abstract

Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN, . Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2006 Feb;4(2):156-76. (2006) Abstract